Corxel agrees $377 million SPAC combination with Amanat to fund oral obesity drug development
Corxel Pharmaceuticals US has agreed to merge with Amanat Acquisition Corp in a SPAC transaction expected to provide approximately $377 million in gross proceeds for its oral obesity drug pipeline.
The proposed business combination includes a committed approximately $300 million private investment in public equity and is intended to finance Phase III development of CX11, an investigational oral small-molecule GLP-1 receptor agonist for obesity.
Assuming no shareholder redemptions, the transaction is expected to support operations through 2029, with completion anticipated in the first half of 2027 subject to shareholder approvals and other closing conditions.
Field | Content |
Article Type | Deals |
Companies | Corxel Pharmaceuticals US; Amanat Acquisition Corp |
Deal Type | Definitive SPAC business combination agreement |
Transaction Status | Announced; not yet completed |
Announcement Date | 26 October 2026 |
Target Company | Corxel Pharmaceuticals US |
SPAC Partner | Amanat Acquisition Corp |
Expected Gross Proceeds | Approximately $377 million assuming no shareholder redemptions |
Committed PIPE Financing | Approximately $300 million |
PIPE Meaning | Private investment in public equity |
Transaction Valuation | Not confirmed in supplied summary |
Acquisition Consideration | Not specified; expected gross proceeds are not acquisition consideration |
Lead Development Asset | CX11 |
Therapeutic Modality | Oral small-molecule GLP-1 receptor agonist |
Therapeutic Area | Metabolic disease; obesity |
Target Indication | Obesity |
Planned Development | Phase III clinical development |
Expected Operating Runway | Through 2029 |
Expected Transaction Closing | First half of 2027 |
Closing Conditions | Subject to shareholder approvals and other customary closing conditions |
What Happened | Corxel Pharmaceuticals US and Amanat Acquisition Corp announced a definitive agreement for a proposed SPAC business combination. |
Why It Matters | The transaction could provide substantial capital to advance an oral GLP-1 obesity treatment through late-stage clinical development. |
Strategic Rationale | Access public-market capital to fund CX11 development and establish a publicly listed obesity-focused biopharmaceutical company. |
Financial Structure | Approximately $377 million in expected gross proceeds includes a committed approximately $300 million PIPE; proceeds depend on transaction assumptions. |
Key Takeaway | The proposed merger could finance Corxel's obesity pipeline into 2029, but completion and the full expected proceeds remain conditional. |
What to Watch | Shareholder approvals, redemption levels, transaction closing, final financing proceeds and CX11 Phase III initiation. |
Primary Source | Corxel Pharmaceuticals US and Amanat Acquisition Corp via GlobeNewswire |
Primary Source URL | https://www.globenewswire.com/news-release/2026/10/26/3387902/0/en/corxel-us-and-amanat-acquisition-corp-announce-definitive-business-combination-agreement-to-create-publicly-listed-obesity-focused-biopharmaceutical-company.html |
Relevant Date | 26 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários